Superdrug has launched a low-cost, over-the-counter “morning-after” pill in its pharmacies in the UK. The retailer is marketing the £10 product as a way to help prevent chlamydia, positioning it as the first such offering on the high street. The announcement comes as STI figures are reported to be rising across the country, according to the coverage.
The articles state that the pill is intended for use after unprotected sex or potential exposure and is designed to reduce the likelihood of infection with chlamydia. The reporting describes Superdrug as the first pharmacy chain to provide this type of pill in high street locations and highlights its accessibility through a single, fixed price point.
However, the provided source excerpts focus mainly on the launch and pricing, without detailing clinical trial data, eligibility requirements, timing windows for effectiveness, or how it compares with other prevention or post-exposure options. The coverage therefore presents the launch and the stated aim—chlamydia prevention—rather than broader outcome measures.
